Ocular and developmental outcomes of a dosing study of bevacizumab for retinopathy of prematurity

To report 2-year ocular and developmental outcomes for infants receiving low doses of intravitreal bevacizumab for type 1 retinopathy of prematurity (ROP).

Source: Journal of AAPOS - January 18, 2023 Category: Opthalmology Authors: David K. Wallace, Amra Hercinovic, Sharon F. Freedman, Eric R. Crouch, Amit R. Bhatt, M. Elizabeth Hartnett, Michael B. Yang, David L. Rogers, Amy K. Hutchinson, William V. Good, Michael X. Repka, Zhuokai Li, Roy W. Beck, Raymond T. Kraker, Susan A. Cotte Tags: Major Article Source Type: research